210 related articles for article (PubMed ID: 2019464)
1. Prognostic value of morphometry and DNA flow-cytometry features of invasive breast cancers detected by population screening: comparison with control group of hospital patients.
Uyterlinde AM; Baak JP; Schipper NW; Peterse HJ; Meijer JW; Vooys PG; Matze E
Int J Cancer; 1991 May; 48(2):173-81. PubMed ID: 2019464
[TBL] [Abstract][Full Text] [Related]
2. Further evaluation of the prognostic value of morphometric and flow cytometric parameters in breast-cancer patients with long follow-up.
Uyterlinde AM; Baak JP; Schipper NW; Peterse H; Matze E; Meijer CJ
Int J Cancer; 1990 Jan; 45(1):1-7. PubMed ID: 2298493
[TBL] [Abstract][Full Text] [Related]
3. Comparative long-term prognostic value of quantitative HER-2/neu protein expression, DNA ploidy, and morphometric and clinical features in paraffin-embedded invasive breast cancer.
Baak JP; Chin D; van Diest PJ; Ortiz R; Matze-Cok P; Bacus SS
Lab Invest; 1991 Feb; 64(2):215-23. PubMed ID: 1671789
[TBL] [Abstract][Full Text] [Related]
4. 'Blind' multicenter evaluation of the prognostic value of DNA image cytometric and morphometric features in invasive breast cancer.
Theissig F; Baak JP; Schuurmans L; Haroske G; Meyer W; Kunze KD
Anal Cell Pathol; 1996 Mar; 10(2):85-99. PubMed ID: 8721952
[TBL] [Abstract][Full Text] [Related]
5. Cell cycle analysis of 932 flow cytometric DNA histograms of fresh frozen breast carcinoma material. Correlations between flow cytometric, clinical, and pathologic variables. MMMCP Collaborative Group. Multicenter Morphometric Mammary Carcinoma Project Collaborative Group.
Bergers E; van Diest PJ; Baak JP
Cancer; 1996 Jun; 77(11):2258-66. PubMed ID: 8635093
[TBL] [Abstract][Full Text] [Related]
6. Comparison of extent of disease and morphometric and DNA flow cytometric prognostic factors in invasive ductal breast cancer.
Uyterlinde AM; Schipper NW; Baak JP
J Clin Pathol; 1987 Dec; 40(12):1432-6. PubMed ID: 2828434
[TBL] [Abstract][Full Text] [Related]
7. S-phase fraction and nuclear size in long term prognosis of patients with breast cancer.
Meyer JS; Province MA
Cancer; 1994 Oct; 74(8):2287-99. PubMed ID: 7922981
[TBL] [Abstract][Full Text] [Related]
8. Two-color, cytokeratin-labeled dna flow cytometric analysis of 332 breast cancers: lack of prognostic value with 12-year follow-up.
Prasad AR; Divine G; Zarbo RJ
Arch Pathol Lab Med; 2001 Mar; 125(3):364-74. PubMed ID: 11231485
[TBL] [Abstract][Full Text] [Related]
9. In lymph node-negative invasive breast carcinomas, specific chromosomal aberrations are strongly associated with high mitotic activity and predict outcome more accurately than grade, tumour diameter, and oestrogen receptor.
Janssen EA; Baak JP; Guervós MA; van Diest PJ; Jiwa M; Hermsen MA
J Pathol; 2003 Dec; 201(4):555-61. PubMed ID: 14648658
[TBL] [Abstract][Full Text] [Related]
10. DNA flow cytometric analysis and prognosis of axillary lymph node-negative breast carcinoma.
Bosari S; Lee AK; Tahan SR; Figoni MA; Wiley BD; Heatley GJ; Silverman ML
Cancer; 1992 Oct; 70(7):1943-50. PubMed ID: 1525770
[TBL] [Abstract][Full Text] [Related]
11. The morphometric prognostic index is the strongest prognosticator in premenopausal lymph node-negative and lymph node-positive breast cancer patients.
van Diest PJ; Baak JP
Hum Pathol; 1991 Apr; 22(4):326-30. PubMed ID: 2050366
[TBL] [Abstract][Full Text] [Related]
12. The value of morphometry to classic prognosticators in breast cancer.
Baak JP; Van Dop H; Kurver PH; Hermans J
Cancer; 1985 Jul; 56(2):374-82. PubMed ID: 4005802
[TBL] [Abstract][Full Text] [Related]
13. Genetic analysis of 53 lymph node-negative breast carcinomas by CGH and relation to clinical, pathological, morphometric, and DNA cytometric prognostic factors.
Hermsen MA; Baak JP; Meijer GA; Weiss JM; Walboomers JW; Snijders PJ; van Diest PJ
J Pathol; 1998 Dec; 186(4):356-62. PubMed ID: 10209483
[TBL] [Abstract][Full Text] [Related]
14. Can we identify the group of small invasive (T1a,b) breast cancers with minimal risk of axillary lymph node involvement? A pathohistological and DNA flow cytometric study.
Bezić J; Samija-Projić I; Projić P; Ljubković J; Capkun V; Tomić S
Pathol Res Pract; 2011 Jul; 207(7):438-42. PubMed ID: 21689895
[TBL] [Abstract][Full Text] [Related]
15. Clinical value of morphometric and DNA flow cytometric variables as independent predictors of survival in epithelial ovarian carcinoma: a 5-year follow-up study.
Veerman MM; van der Wurff AA; van de Water M; Kruitwagen RF; Feijen HW; Vos MC
Int J Gynecol Pathol; 2009 Sep; 28(5):432-41. PubMed ID: 19696612
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of S-phase fraction in lymph-node-negative breast cancer by image and flow cytometric analysis.
Peiró G; Lerma E; Climent MA; Seguí MA; Alonso MC; Prat J
Mod Pathol; 1997 Mar; 10(3):216-22. PubMed ID: 9071729
[TBL] [Abstract][Full Text] [Related]
17. DNA index and S-phase fraction and their combination as prognostic factors in operable ductal breast carcinoma.
Joensuu H; Toikkanen S; Klemi PJ
Cancer; 1990 Jul; 66(2):331-40. PubMed ID: 2164437
[TBL] [Abstract][Full Text] [Related]
18. Limited prognostic value of cellular DNA content to classical and morphometrical parameters in invasive ductal breast cancer.
Uyterlinde AM; Schipper NW; Baak JP; Peterse H; Matze E
Am J Clin Pathol; 1988 Mar; 89(3):301-7. PubMed ID: 2831704
[TBL] [Abstract][Full Text] [Related]
19. Prognostic implications of different cell cycle analysis models of flow cytometric DNA histograms of 1,301 breast cancer patients: results from the Multicenter Morphometric Mammary Carcinoma Project (MMMCP).
Bergers E; Baak JP; van Diest PJ; van Gorp LH; Kwee WS; Los J; Peterse HL; Ruitenberg HM; Schapers RF; Somsen JG; van Beek MW; Bellot SM; Fijnheer J
Int J Cancer; 1997 Jun; 74(3):260-9. PubMed ID: 9221802
[TBL] [Abstract][Full Text] [Related]
20. Nuclear morphometry and mitotic indexes as prognostic factors in breast cancer.
Aaltomaa S; Lipponen P; Eskelinen M; Alhava E; Syrjänen K
Eur J Surg; 1991 May; 157(5):319-24. PubMed ID: 1678644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
